iBio, AstralBio announce development of antibody inhibiting Activin E
Bio (IBIO) in collaboration with AstralBio announced the development of an antibody that inhibits the function of Activin E, a promising ...
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in ...
FierceBiotech6d
iBio pens $29M biobucks deal with AstralBio for obesity med designed to preserve muscle mass
San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...
Yahoo Finance19h
iBio, Inc. (IBIO)
An update from Ibio ( (IBIO) ) is now available. iBio, Inc. announced an exclusive agreement with AstralBio to license a long-acting anti-myostatin antibody, IBIO-600, designed for obesity and ...
BioWorld2d
Ibio licenses long-acting anti-myostatin antibody from Astralbio
Ibio Inc. has expanded its cardiometabolic and obesity treatment development program by in-licensing a long-acting anti-myostatin antibody from Astralbio Inc. The antibody, now named IBIO-600, was ...
iBio Expands Pipeline with New Antibody Agreement
An update from Ibio ( (IBIO) ) is now available. iBio, Inc. announced an exclusive agreement with AstralBio to license a long ...
Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform
Bio advances obesity treatment with IBIO-600, a long-acting anti-myostatin antibody designed for subcutaneous use, targeting ...
manilatimes7d
iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
Pursuant to the agreement, AstralBio will receive an upfront payment of $750,000, which iBio has paid by issuing its common stock to AstralBio. In addition, AstralBio will be eligible for development ...